Degarelix (Firmagon)

1. Overview

Degarelix is a synthetic linear decapeptide amide that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist, developed by Ferring Pharmaceuticals for the treatment of advanced hormone-dependent prostate cancer [11][13]. Its chemical name is N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[(hexahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]amino-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, with the empirical formula C82H103ClN18O16 and a molecular weight of 1632.3 Da [22].

Structurally, degarelix is derived from native GnRH (a decapeptide) but incorporates seven unnatural amino acid residues, five of which are D-amino acids, conferring enhanced metabolic stability and improved receptor binding properties [11][13]. The amino acid sequence is: Ac-D-2Nal(1)-D-4Cpa(2)-D-3Pal(3)-Ser(4)-4Aph(L-Hor)(5)-D-4Aph(Cbm)(6)-Leu(7)-Lys(iPr)(8)-Pro(9)-D-Ala(10)-NH2. The molecule contains eleven chiral centers -- ten in the peptide backbone and one additional center in the hydroorotyl side chain at position 5 [11]. The presence of D-amino acids at positions 1, 2, 3, 6, and 10 protects against enzymatic degradation, while the acetylated N-terminus and amidated C-terminus further enhance stability.

Degarelix was approved by the U.S. Food and Drug Administration on December 24, 2008 under the brand name Firmagon for the treatment of patients with advanced prostate cancer [22]. It was subsequently approved by the European Medicines Agency (EMA) in 2009 under the same brand name. Unlike GnRH agonists such as leuprolide and goserelin, degarelix produces immediate suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone without the initial hormonal surge (clinical flare) that necessitates concomitant anti-androgen therapy [1][13].

Molecular Weight

1632.3 Da

Structure

Synthetic linear decapeptide amide (7 unnatural amino acids, 5 D-amino acids)

Half-life

~53 days (terminal, depot release); ~43 days (starting dose)

Bioavailability

Subcutaneous depot (concentration-dependent)

Routes

Subcutaneous injection (deep SC, abdominal)

FDA Status

Approved (Firmagon, December 24, 2008)

Approved Indication

Advanced hormone-dependent prostate cancer

2. Mechanism of Action

Degarelix exerts its therapeutic effect through competitive, reversible blockade of GnRH receptors on gonadotroph cells in the anterior pituitary gland [11][13]. This mechanism produces several pharmacologically distinct advantages over GnRH agonists.

Competitive GnRH receptor antagonism. Native GnRH (also called LHRH) is a decapeptide released in pulsatile fashion from the hypothalamus that binds to GnRH receptors on anterior pituitary gonadotrophs, stimulating the synthesis and secretion of LH and FSH [16]. Degarelix binds directly to these same receptors with high affinity, competitively blocking the binding of endogenous GnRH. This immediately interrupts the hypothalamic-pituitary-gonadal axis signaling cascade, reducing LH and FSH secretion within hours of administration [1][13]. Because degarelix is an antagonist rather than an agonist, there is no initial receptor activation, no stimulation of gonadotropin release, and therefore no testosterone surge or clinical flare.

Immediate testosterone suppression without flare. With GnRH agonists (leuprolide, goserelin, triptorelin), initial receptor stimulation causes a transient increase in LH and testosterone lasting 1 to 3 weeks (the "testosterone flare"), which can exacerbate disease symptoms including bone pain, urinary obstruction, and spinal cord compression in patients with advanced or metastatic disease [13][16]. In the pivotal CS21 trial, 96.1% of patients receiving degarelix 240/80 mg achieved castrate testosterone levels (0.5 ng/mL or below) within 3 days, compared to 0% of leuprolide-treated patients at the same time point [1]. By day 28, 100% of degarelix patients had achieved castration. This eliminates the need for anti-androgen "flare protection" with agents such as bicalutamide that are routinely co-administered with GnRH agonists during the first weeks of treatment.

Superior FSH suppression. GnRH antagonists suppress FSH to significantly lower levels than GnRH agonists [21]. While the clinical significance of FSH suppression in prostate cancer is still being investigated, FSH receptors have been identified on prostate cancer cells and tumor vasculature, and profound FSH suppression may contribute to improved tumor control and a potential delay in progression to castration-resistant disease [10][21].

Depot formation and sustained release. Following subcutaneous injection, degarelix forms a gel-like depot at the injection site due to its physicochemical properties in aqueous solution [12]. This depot allows sustained drug release in a biphasic pattern: an initial fast-release phase providing rapid onset of action, followed by a slow-release phase that maintains therapeutic plasma concentrations throughout the 28-day dosing interval [12][22]. The long terminal half-life (approximately 53 days for the starting dose) reflects the slow dissociation from this subcutaneous depot rather than systemic elimination kinetics.

3. Researched Applications

Advanced Prostate Cancer -- Androgen Deprivation Therapy (Strong Evidence -- FDA Approved)

The CS21 pivotal trial was a 12-month, randomized, open-label, parallel-group Phase 3 study in 610 patients with prostate cancer of any stage requiring androgen deprivation therapy [1]. Patients were randomized to degarelix 240/80 mg (starting/maintenance), degarelix 240/160 mg, or leuprolide 7.5 mg monthly. The primary endpoint -- probability of testosterone 0.5 ng/mL or below from day 28 to day 364 -- was achieved in 97.2%, 98.3%, and 96.4% of patients in the three groups respectively, confirming non-inferiority of degarelix to leuprolide [1]. Degarelix produced significantly faster testosterone suppression (96.1% at day 3 vs 0% for leuprolide) and significantly faster PSA decline (64% median PSA reduction at day 14 vs 18% for leuprolide) [1]. Injection site reactions occurred in 40% of degarelix patients versus fewer than 1% of leuprolide patients, reflecting the subcutaneous depot formation.

Long-Term Androgen Deprivation (Strong Evidence)

The CS21A extension trial followed patients from CS21 for up to 5 years, with leuprolide patients crossing over to degarelix [2][3]. Sustained testosterone suppression was maintained throughout, and the PSA progression-free survival advantage originally observed for degarelix over leuprolide during year 1 remained consistent at 5 years [3]. In the crossover group, the PSA progression hazard rate was halved after switching from leuprolide to degarelix (0.20 to 0.08 events/year) [2]. A total of 42% of patients completed the full extension phase, and no new safety signals emerged [3].

PSA Progression-Free Survival Advantage (Moderate Evidence)

Post hoc analysis of CS21 by Tombal et al. demonstrated that the risk of PSA failure was significantly lower with degarelix 240/80 mg versus leuprolide during the first year (p=0.05, log-rank test) [4]. This benefit was most pronounced in patients with higher disease burden: in those with baseline PSA greater than 20 ng/mL, time to 25% PSA progression was 514 days with degarelix versus 303 days with leuprolide (p=0.01) [4][10].

Lower Urinary Tract Symptom Relief (Moderate Evidence)

Two Phase 3b trials (CS30 and CS35) and pooled analyses evaluated degarelix versus goserelin plus bicalutamide for LUTS relief in patients with prostate cancer [8][9][23]. Degarelix demonstrated non-inferior or superior relief of LUTS as measured by International Prostate Symptom Score (IPSS), with significantly greater quality-of-life improvement at week 12 (85% vs 46%, p=0.01) [8]. Prostate volume reduction was also greater with degarelix (42% vs 25%) [8]. These benefits may relate to direct effects of GnRH antagonism on extra-pituitary GnRH receptors in the lower urinary tract [23].

Cardiovascular Safety Considerations (Moderate Evidence)

The Albertsen 2014 pooled analysis of six prospective randomized trials (n=2,328) found that men with pre-existing cardiovascular disease treated with degarelix had a 56% lower risk of cardiac events or death compared to LHRH agonists (6.5% vs 14.7%) during the first year of treatment [6]. An earlier analysis by Schroder et al. (2011) also suggested a cardiovascular advantage for degarelix [20]. However, the PRONOUNCE trial (2021), a prospective Phase 4 study specifically designed to test this hypothesis in 545 men with prostate cancer and atherosclerotic cardiovascular disease, found no significant difference in major adverse cardiovascular events between degarelix (5.5%) and leuprolide (4.1%), with HR 1.28 (95% CI 0.59-2.79, p=0.53) [7]. Importantly, the PRONOUNCE trial was terminated prematurely due to slow enrollment and achieved only 60% of planned accrual, leaving it substantially underpowered [7].

4. Clinical Evidence Summary

5. Dosing in Research

The FDA-approved dosing regimen for degarelix consists of a loading dose of 240 mg administered as two subcutaneous injections of 120 mg each (at a concentration of 40 mg/mL), followed by a maintenance dose of 80 mg administered as a single subcutaneous injection (at a concentration of 20 mg/mL) every 28 days [22].

Degarelix is supplied as a lyophilized powder that must be reconstituted with sterile water for injection immediately before use. The reconstituted solution is administered by deep subcutaneous injection into the abdominal region. The two 120 mg loading dose injections should be given at different injection sites. Injection sites should be rotated to minimize local reactions.

In the CS21 pivotal trial, two maintenance dose levels were evaluated: 80 mg and 160 mg monthly, with both demonstrating equivalent efficacy [1]. The 80 mg dose was selected for commercial development based on the comparable efficacy and the principle of using the lowest effective dose.

A three-month depot formulation (480 mg) was investigated in the CS35 trial comparing degarelix with goserelin 10.8 mg quarterly, and in a Japanese Phase 3 study [9][15]. While the three-month formulation demonstrated non-inferior testosterone suppression, its clinical development program was limited by enrollment challenges.

Pharmacokinetic parameters. Following the 240 mg starting dose, mean Cmax is 26.2 ng/mL (reached within approximately 2 days) with mean AUC of 1054 ng-day/mL [22]. The biphasic elimination from the subcutaneous depot yields a terminal half-life of approximately 53 days for the starting dose and 28 days for the maintenance dose [12][22]. There is no hepatic first-pass metabolism, and the drug is degraded by peptide hydrolysis during passage through the hepatobiliary system, with approximately 70-80% excreted as peptide fragments in feces [22].

6. Safety and Side Effects

The safety profile of degarelix has been characterized across multiple Phase 3 clinical trials involving over 2,500 patients, with follow-up extending to 5 years in the CS21A extension [1][3][5][22].

Injection site reactions. The most distinctive adverse effect of degarelix is injection site reactions, which occurred in approximately 40% of patients in the pivotal CS21 trial (compared to fewer than 1% with intramuscular leuprolide) [1]. These reactions include pain, erythema, swelling, induration, and nodule formation at the injection site. They are predominantly mild to moderate in severity, occur most frequently after the first (loading) dose, and decrease in incidence with subsequent maintenance doses [22]. Injection site reactions led to treatment discontinuation in fewer than 1% of patients. Rare serious injection site reactions including infection, abscess, and necrosis have been reported in post-marketing surveillance [22].

Hot flashes. Hot flashes (hot flushes) are the most common systemic adverse effect, occurring in approximately 26% of degarelix-treated patients [1][22]. This is a class effect of all androgen deprivation therapies and reflects the hypogonadal state achieved by treatment.

Hepatic effects. Mild, transient elevations in serum transaminases (ALT, AST) and gamma-glutamyltransferase (GGT) have been observed in more than 10% of patients [22]. These elevations are typically asymptomatic, not accompanied by bilirubin increases, and resolve spontaneously without dose modification.

Body weight and metabolic effects. Weight gain (approximately 2-4 kg over 12 months), decreased bone mineral density, and metabolic changes (insulin resistance, lipid alterations) are class effects shared with all forms of androgen deprivation therapy [10][22].

Cardiovascular effects. In the CS21 trial, ischemic heart disease was reported in 4% of degarelix patients versus 10% of leuprolide patients [5]. QTcF prolongation was observed in both groups with a median change from baseline of 12.3 ms for degarelix and 16.7 ms for leuprolide [5]. Markedly abnormal QTcF values (500 ms or greater) were rare in both groups [5].

Other adverse effects. Additional reported adverse effects include fatigue, musculoskeletal pain, arthralgia, urinary tract infection, diarrhea, constipation, erectile dysfunction, gynecomastia, and insomnia, all of which are consistent with the effects of androgen deprivation [22].

Contraindications. Degarelix is contraindicated in patients with known hypersensitivity to degarelix or any of its excipients, in women (the drug is not indicated for use in women), and in pediatric patients [22]. It should be used with caution in patients with severe hepatic impairment, known QT prolongation, or electrolyte abnormalities, and in patients taking Class IA or Class III antiarrhythmic medications.

7. Regulatory Status

United States (FDA). Degarelix (Firmagon) was approved by the FDA on December 24, 2008 for the treatment of patients with advanced prostate cancer [22]. The approval was based primarily on the CS21 pivotal trial demonstrating non-inferiority to leuprolide in achieving and maintaining castrate testosterone levels [1]. Firmagon is marketed by Ferring Pharmaceuticals in the United States.

European Union (EMA). The European Medicines Agency granted marketing authorization for Firmagon in February 2009 for the treatment of adult male patients with advanced hormone-dependent prostate cancer. The EMA approval covers the same 240/80 mg dosing regimen.

Other markets. Degarelix has been approved in over 80 countries worldwide, including Canada, Japan (where a three-month formulation was also developed), South Korea, and Australia [17]. The drug has been included in clinical guidelines from major urological and oncological societies as a recommended option for androgen deprivation therapy, particularly in settings where avoidance of testosterone flare is clinically important.

Patent and generic status. The original Ferring patents for degarelix have begun expiring in major markets, and generic/biosimilar development programs are underway in several countries.

2025 Updates

A 2025 systematic review and meta-analysis comparing degarelix with GnRH agonists confirmed that degarelix has a higher overall adverse event rate (59.7% vs 48.4%) but does not lead to higher rates of severe complications (10.8% vs 11.8%) or treatment discontinuation (5.5% vs 5.5%). The analysis also confirmed a reduced risk of heart failure with degarelix (HR 0.56, 95% CI 0.36-0.88). A separate 2025 real-world adherence study found that relugolix had substantially higher 12-month adherence (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%), highlighting the challenge of monthly injectable regimens for patient compliance.

8. Pharmacokinetics

8.1 Depot Formation and Release Kinetics

Degarelix's unique pharmacokinetic profile is defined by its self-forming gel depot at the subcutaneous injection site [12][13][22]:

Depot mechanism: Following subcutaneous injection of the reconstituted solution (40 mg/mL for the loading dose, 20 mg/mL for maintenance), degarelix peptide molecules aggregate in situ to form a gel-like depot due to the amphiphilic nature of the peptide at physiological pH and ionic strength. This depot functions as a drug reservoir, releasing degarelix in a biphasic pattern [12]:

• Initial fast-release phase (days 1-2): Rapid dissolution from the depot periphery produces peak plasma concentrations (Cmax ~26.2 ng/mL for the 240 mg loading dose) within approximately 2 days. This rapid initial release is responsible for the immediate testosterone suppression (96.1% achieving castrate levels by day 3) [1][22].
• Sustained slow-release phase (days 3-28+): Gradual erosion of the gel depot core maintains therapeutic plasma concentrations throughout the dosing interval. The rate of release is governed by the physical dissolution of peptide aggregates rather than enzymatic degradation of a polymer matrix (as in PLGA-based depot systems like leuprolide LAR or goserelin).

8.2 Key Pharmacokinetic Parameters

| PK Parameter | 240 mg Loading Dose | 80 mg Maintenance Dose | |---|---|---| | Cmax | 26.2 ng/mL | 11.4 ng/mL | | Tmax | ~2 days | ~2 days | | AUC(0-28d) | 1054 ng-day/mL | 635 ng-day/mL | | Terminal half-life | ~53 days | ~28 days | | Trough concentration (day 28) | ~9-11 ng/mL | ~5-7 ng/mL | | Bioavailability | Not precisely determined (SC depot) | Same | | Protein binding | ~90% (albumin) | ~90% | | Volume of distribution | ~1 L/kg | ~1 L/kg |

The long terminal half-life (~53 days for loading dose, ~28 days for maintenance) reflects the slow dissociation of drug from the subcutaneous depot rather than slow systemic elimination. Once released from the depot, degarelix is rapidly cleared from plasma through peptide hydrolysis [12][22].

8.3 Metabolism and Elimination

Degarelix follows a unique metabolic pathway distinct from most peptide drugs [22]:

• No CYP450 involvement: Degarelix is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes, eliminating conventional drug-drug interaction concerns
• Peptide hydrolysis: Circulating degarelix is degraded by ubiquitous tissue and plasma peptidases into inactive peptide fragments
• Hepatobiliary excretion: Approximately 70-80% of degraded fragments are excreted in feces via hepatobiliary elimination
• Renal excretion: Approximately 20-30% of dose is eliminated renally
• No dose adjustment required: Neither hepatic nor renal impairment requires dose modification, as the primary pharmacokinetic determinant is depot release rate rather than systemic clearance [22]

8.4 Pharmacokinetic Comparison with GnRH Agonist Depots

| Parameter | Degarelix (Antagonist) | Leuprolide Depot (Agonist) | Goserelin Implant (Agonist) | |---|---|---|---| | Depot type | Self-forming gel | PLGA microspheres | Solid PLGA implant | | Depot mechanism | Peptide aggregation in situ | Polymer erosion | Polymer hydrolysis | | Release pattern | Biphasic (fast then sustained) | Triphasic (burst, lag, sustained) | Biphasic (burst then sustained) | | Lag phase | None | Yes (days 2-14; may require SC supplementation) | Minimal | | Terminal half-life | ~53 days (depot-dependent) | ~3 hours (solution); ~28 days (depot release) | ~4.2 hours (solution); ~28 days (depot) | | Tmax for hormonal effect | Day 1-3 (immediate castration) | Day 21-28 (after flare) | Day 21-28 (after flare) | | Injection site reactions | 40% (depot-related nodule/pain) | less than 5% | 5-10% (16-gauge needle) |

9. Dose-Response Relationships

9.1 Testosterone Suppression Dose-Response

The CS21 pivotal trial and the Phase 2 dose-finding study (Gittelman et al. 2008) established the dose-response relationship for testosterone suppression [1][14]:

Phase 2 dose-finding (Gittelman et al.): Evaluated seven dose arms with different loading/maintenance combinations:

| Loading Dose (mg) | Maintenance Dose (mg) | Castrate T (at or below 0.5 ng/mL) at Day 3 | Castrate T Maintained (Day 28-364) | |---|---|---|---| | 200 | 60 | 90% | 87.5% | | 200 | 80 | 93% | 91.2% | | 240 | 80 | 96.1% | 97.2% | | 240 | 160 | 97% | 98.3% |

The 240/80 mg regimen was selected for commercial development as the lowest dose combination achieving greater than 95% castration rate at both day 3 and throughout the 12-month treatment period. The 240/160 mg regimen offered only marginally higher rates and was not justified by the dose-proportional increase in injection volume and local reactions [1][14].

9.2 PSA Response Kinetics

Degarelix produces faster and more profound early PSA decline compared to leuprolide [1][4]:

| Timepoint | Degarelix 240/80 (Median PSA Decline) | Leuprolide 7.5 mg (Median PSA Decline) | p-value | |---|---|---|---| | Day 14 | 64% | 18% | less than 0.001 | | Day 28 | 85% | 68% | less than 0.01 | | Day 56 | 95% | 93% | NS | | Day 364 | 97% | 96% | NS |

The early PSA advantage (64% vs 18% at day 14) reflects the absence of testosterone flare and the immediate receptor blockade. By 2 months, PSA suppression converges between degarelix and leuprolide. However, the early advantage may have clinical significance in patients with high-volume or symptomatic disease where rapid tumor control is critical [4][10].

9.3 Dose-Response in High-Risk Subgroups

Post hoc analysis by Tombal et al. (2010) demonstrated that the PSA-PFS advantage of degarelix over leuprolide was most pronounced in patients with higher disease burden [4]:

• Baseline PSA at or below 20 ng/mL: No significant PSA-PFS difference (degarelix = leuprolide)
• Baseline PSA greater than 20 ng/mL: PSA-PFS significantly longer with degarelix (514 vs 303 days, p=0.01)
• Metastatic disease: Greater magnitude of PSA-PFS benefit with degarelix
• High Gleason score (8-10): Trend toward improved PSA-PFS with degarelix

This dose-response by disease burden suggests that degarelix's pharmacokinetic advantage (immediate castration without flare) translates to greater clinical benefit when tumor volume is high and rapid testosterone suppression is most needed [4][10].

10. Comparative Effectiveness

10.1 Degarelix vs. Leuprolide (Pivotal CS21 Comparison)

The CS21 trial provides the most direct comparison data [1][3][4][5]:

| Endpoint | Degarelix 240/80 mg | Leuprolide 7.5 mg | Significance | |---|---|---|---| | Castrate T (day 28-364) | 97.2% | 96.4% | Non-inferior | | Castrate T by day 3 | 96.1% | 0% | Degarelix superior | | PSA decline at day 14 | 64% | 18% | Degarelix superior | | 1-year PSA-PFS | Superior | Reference | p=0.05 (log-rank) | | PSA-PFS (baseline PSA greater than 20) | 514 days | 303 days | p=0.01 | | Testosterone flare | 0% | 80%+ | Degarelix advantage | | S-ALP reduction (bone marker) | Greater decrease | Less decrease | Favors degarelix | | Injection site reactions | 40% | less than 1% | Leuprolide advantage | | Hot flashes | 26% | 21% | Comparable |

10.2 Degarelix vs. Relugolix (Orgovyx)

Relugolix (Orgovyx), approved by the FDA in December 2020, is an oral GnRH antagonist that has transformed the competitive landscape for degarelix [7]:

| Parameter | Degarelix (Firmagon) | Relugolix (Orgovyx) | |---|---|---| | Route | Subcutaneous injection | Oral (once daily) | | Class | Peptide GnRH antagonist | Non-peptide oral GnRH antagonist | | Loading | 240 mg SC (two injections) | 360 mg oral (day 1 loading) | | Maintenance | 80 mg SC monthly | 120 mg orally once daily | | Castrate T by day 4 | 96.1% (by day 3) | 56% (by day 4) | | Castrate T at day 15 | ~100% | 97% | | Sustained castration (48 weeks) | 97.2% | 96.7% | | Testosterone flare | None | None | | Testosterone recovery after stop | Median ~2-3 months | Median ~90 days | | MACE (HERO trial) | N/A (not in HERO) | 2.9% vs 6.2% (leuprolide); HR 0.46 | | Injection site reactions | 40% | None (oral) | | GI side effects | Minimal | Diarrhea (12%), constipation (12%), nausea (9%) | | Drug interactions | None significant | CYP3A4 inducers reduce efficacy; P-gp inhibitors increase levels | | Compliance concern | Monthly clinic visit ensures adherence | Daily oral dosing requires patient compliance | | FDA approval | 2008 (prostate cancer) | 2020 (advanced prostate cancer) |

Clinical positioning: Relugolix's oral route and favorable cardiovascular signal (HERO trial: 54% lower MACE vs leuprolide) have positioned it as a preferred GnRH antagonist in many treatment guidelines, particularly for patients with pre-existing cardiovascular disease. Degarelix retains an advantage in settings where treatment compliance is a concern (guaranteed monthly administration by healthcare provider) and where the most rapid possible testosterone suppression is needed (96.1% by day 3 vs 56% by day 4 with relugolix) [7].

10.3 Degarelix vs. GnRH Agonists (Class Comparison)

Advantages of degarelix over GnRH agonists:

• No testosterone flare; no need for anti-androgen flare protection
• Faster time to castration (3 days vs 21-28 days)
• More profound FSH suppression (potential tumor control benefit)
• Possibly favorable cardiovascular profile (Albertsen pooled analysis: 56% lower cardiac events in pre-existing CVD)
• Superior early PSA suppression and PSA-PFS in high-burden disease
• Superior LUTS relief and prostate volume reduction

Disadvantages of degarelix vs. GnRH agonists:

• High injection site reaction rate (40% vs less than 5%)
• Monthly injections required (no 3- or 6-month depot available commercially)
• More complex injection technique (reconstitution, two separate sites for loading dose)
• Higher drug acquisition cost in some markets

11. Enhanced Safety Profile

11.1 Injection Site Reaction Characterization

The most distinctive safety issue for degarelix is the high rate of injection site reactions (ISRs), extensively characterized across clinical trials [1][3][22]:

| ISR Type | Loading Dose (240 mg) | Maintenance Dose (80 mg) | |---|---|---| | Any ISR | ~40% | ~5-10% per injection | | Pain | 35% | 5% | | Erythema | 17% | 3% | | Swelling | 6% | less than 1% | | Induration/nodule | 5% | 2% | | Treatment discontinuation due to ISR | less than 1% | less than 1% |

ISR characteristics: predominantly mild to moderate (grade 1-2); onset within hours of injection; typical duration 1-3 days; related to gel depot formation; decrease in frequency and severity with successive maintenance injections. The loading dose ISR rate (40%) is higher due to the larger injection volume (2 x 3 mL vs 1 x 4 mL for maintenance) and higher peptide concentration (40 mg/mL vs 20 mg/mL) [22].

11.2 Cardiovascular Safety -- Detailed Evidence Assessment

The cardiovascular safety question for degarelix has been addressed across multiple analyses with somewhat contradictory results [5][6][7][20]:

Evidence suggesting CV advantage for degarelix:

• Klotz 2010 (CS21 post hoc): Ischemic heart disease 4% vs 10% (leuprolide) [5]
• Albertsen 2014 (pooled 6 RCTs, n=2,328): In pre-existing CVD, cardiac events/death 6.5% vs 14.7% (HR ~0.44 favoring degarelix) [6]
• Schroder 2011: Consistent CV advantage signal in prospective data [20]

Evidence showing no significant difference:

• PRONOUNCE trial (2021, Phase 4 RCT, n=545): MACE 5.5% (degarelix) vs 4.1% (leuprolide), HR 1.28 (95% CI 0.59-2.79, p=0.53). However, the trial was terminated early (60% accrual) and substantially underpowered [7]

Current interpretation: The pooled observational data suggest a potential cardiovascular advantage for GnRH antagonists over agonists in patients with pre-existing CVD. However, the only prospective RCT specifically designed to test this hypothesis (PRONOUNCE) was inconclusive due to premature termination. Major guidelines (EAU, AUA) note the potential advantage but do not mandate GnRH antagonist use based on cardiovascular risk alone.

11.3 Hepatic Safety

Transaminase elevations are more common with degarelix than with GnRH agonists [22]:

• ALT/AST elevation (any grade): 10-13%
• Grade 3+ hepatic events: less than 1%
• GGT elevation: 10%
• Pattern: transient, asymptomatic, typically normalizes without dose modification
• Mechanism: likely related to androgen deprivation effects on hepatic metabolism rather than direct hepatotoxicity
• Monitoring: liver function tests recommended at baseline and periodically during treatment

11.4 QT Prolongation Risk

ADT-associated QT prolongation is a class effect but has been specifically studied for degarelix [5][22]:

• Mean QTcF change from baseline: +12.3 ms (degarelix) vs +16.7 ms (leuprolide) in CS21
• QTcF greater than 450 ms: comparable rates between groups
• QTcF greater than 500 ms: rare in both groups (less than 1%)
• Recommendation: ECG at baseline in patients with cardiac history or on QT-prolonging medications; avoid concomitant Class IA/III antiarrhythmics when possible

11.5 Comparison of Safety Profiles Across ADT Options

| Safety Parameter | Degarelix | Leuprolide | Goserelin | Relugolix | |---|---|---|---|---| | Testosterone flare | No | Yes | Yes | No | | Injection site reactions | 40% (loading) | less than 5% | 5-10% | N/A (oral) | | Hot flashes | 26% | 21-30% | 57-75% | 23% | | Hepatic effects | 10-13% ALT/AST elevation | 5-8% | less than 5% | 5-8% | | GI side effects | Minimal | Minimal | Minimal | 12% diarrhea | | CV events (pre-existing CVD) | Possibly lower (pooled data) | Higher (pooled data) | Similar to leuprolide | Lower vs leuprolide (HERO trial) | | Drug interactions | None significant | None significant | None significant | CYP3A4/P-gp interactions | | Bone loss | Class effect (2-3%/year) | Same | Same | Same |

12. Related Peptides

See also: Leuprolide (Lupron), Goserelin (Zoladex)

13. References

1. [1] Klotz L, Boccon-Gibod L, Shore ND, et al. (2008). The efficacy and safety of degarelix - a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. DOI PubMed
2. [2] Crawford ED, Tombal B, Miller K, et al. (2011). A phase III extension trial with a 1-arm crossover from leuprolide to degarelix - comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. DOI PubMed
3. [3] Crawford ED, Shore ND, Moul JW, et al. (2014). Long-term tolerability and efficacy of degarelix - 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. DOI PubMed
4. [4] Tombal B, Miller K, Boccon-Gibod L, et al. (2010). Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. DOI PubMed
5. [5] Klotz L, Miller K, Crawford ED, et al. (2010). Cardiovascular safety of degarelix - results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. DOI PubMed
6. [6] Albertsen PC, Klotz L, Tombal B, et al. (2014). Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. DOI PubMed
7. [7] Lopes RD, Higano CS, Slovin SF, et al. (2021). Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer - the primary results of the PRONOUNCE randomized trial. Circulation. DOI PubMed
8. [8] Anderson J, Al-Ali G, Wirth M, et al. (2013). Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer - results from a phase IIIb study (CS30). Urol Oncol. DOI PubMed
9. [9] Tombal B, Tammela TLJ, Boccon-Gibod L, et al. (2012). Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer - degarelix vs goserelin plus bicalutamide. Clin Drug Investig. DOI PubMed
10. [10] Shore ND. (2013). Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. DOI PubMed
11. [11] Van Poppel H, Tombal B, de la Rosette JJ, et al. (2008). Degarelix - a novel gonadotropin-releasing hormone (GnRH) receptor blocker. Drugs Today. DOI PubMed
12. [12] Princivalle M, Broqua P, White R, et al. (2007). Gonadotropin-releasing hormone antagonists - pharmacokinetics of degarelix. Endocr Relat Cancer. DOI PubMed
13. [13] Steinberg M. (2009). Degarelix - a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther. DOI PubMed
14. [14] Gittelman M, Pommerville PJ, Persson BE, et al. (2008). A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. DOI PubMed
15. [15] Ozono S, Tsukamoto T, Naito S, et al. (2018). Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer - a phase III study. Cancer Sci. DOI PubMed
16. [16] Garnick MB, Mottet N. (2004). New treatment paradigm for prostate cancer - abarelix (Plenaxis) and other GnRH antagonists. Rev Urol. PubMed
17. [17] Sun Y, Xie L, Xu T, et al. (2020). Efficacy and safety of degarelix in patients with prostate cancer - results from a phase III study in China. Asian J Urol. DOI PubMed
18. [18] Sciarra A, Fasulo A, Ciardi A, et al. (2016). A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists. Medicine (Baltimore). DOI PubMed
19. [19] Klotz L, Boccon-Gibod L, Shore ND, et al. (2010). Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide - results from a 12-month, comparative, phase III study. BJU Int. DOI PubMed
20. [20] Schroder FH, Tombal B, Miller K, et al. (2011). Gonadotropin-releasing hormone blockers and cardiovascular disease risk - analysis of prospective clinical trials of degarelix. Eur Urol. DOI PubMed
21. [21] Margel D, Peer A, Groshar D, et al. (2019). FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Andrology. DOI PubMed
22. [22] U.S. Food and Drug Administration. (2008). Firmagon (degarelix for injection) prescribing information. FDA Label. PubMed
23. [23] Tombal B, Tammela TLJ, Freedland SJ, et al. (2017). Degarelix versus goserelin plus bicalutamide - pooled analysis of lower urinary tract symptoms. Future Oncol. DOI PubMed